Jacob Diskin, MD
Ophthalmology · Birmingham, MINPI 1871053751
Payments from drug & device makers
Across 102 payments — averaging $49.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- Alcon$556
- Bausch & Lomb Americas Inc.$427
- NEW World Medical,inc.$326
- AbbVie$305
- Glaukos Corporation$217
- plus $1K from 16 others
What the payments were for
- Travel & lodging$1,46229%
- Food & beverage$3,47569%
- Education$1052%
- Entertainment$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 23 | $1,998 |
| Alcon | 10 | $556 |
| Bausch & Lomb Americas Inc. | 16 | $427 |
| NEW World Medical,inc. | 4 | $326 |
| AbbVie(2 entities) | 6 | $305 |
| Glaukos Corporation | 2 | $217 |
| Biotissue Holdings Inc. | 5 | $201 |
| Amgen | 4 | $157 |
| Sight Sciences, Inc. | 2 | $142 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $110 |
| Tarsus Pharmaceuticals, Inc. | 4 | $105 |
| Oyster Point Pharma, Inc. | 3 | $84 |
| Ocular Therapeutix, Inc. | 4 | $81 |
| Novartis | 1 | $78 |
| Dompe US, Inc. | 4 | $77 |
| Sun Pharmaceutical Industries Inc. | 4 | $76 |
| Optos, Inc. | 1 | $30 |
| Rayner Intraocular Lenses Limited | 1 | $27 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 1 | $24 |
| Harrow Eye, LLC | 1 | $21 |
| Thea Pharma Inc. | 1 | $16 |
| Beaver-visitec International, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELLARIS$1,351
- Crystalens Accommodating IOL (AT-52AO)$1,351
- Trulign IOL$1,351
- Akreos AO IOL$1,351
- enVista MX60 IOL$1,351
- MIEBO$225
- iStent Infinite$195
- iDoseTR$195
- AcrySof IQ VIVITY$144
- XIIDRA$125
- TRYPTYR$121
- DURYSTA$116
- OMNI(R) SURGICAL SYSTEM (US)$109
- Clareon$107
How this compares
$5,072 in reported general payments places this provider in the 80th percentile of 674 ophthalmology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 70 | $74,114 |
| LumiganBimatoprost | 56 | $22,726 |
| RocklatanNetarsudil Mesylat/Latanoprost | 30 | $15,515 |
| Restasis MultidoseCyclosporine | 13 | $11,334 |
| Cyclosporine | 25 | $10,945 |
| VyzultaLatanoprostene Bunod | 23 | $6,422 |
| Latanoprost | 460 | $6,353 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 21 | $5,623 |
| CombiganBrimonidine Tartrate/Timolol | 15 | $5,386 |
| Brimonidine Tartrate | 189 | $4,569 |
| Loteprednol Etabonate | 13 | $4,216 |
| Timolol Maleate | 271 | $3,463 |
| Prednisolone Acetate | 76 | $2,702 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 34 | $2,541 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 77 | $1,716 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Restasis Multidose, Combigan | $305 | $113,559154 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $427 | $6,42223 claims |
| AlconSimbrinza | $556 | $5,62321 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $1,998 | $4,21613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 674 ophthalmology providers in Michigan.
Other ophthalmology in Birmingham
- Timothy PageBirmingham$324K
- Mahdi BashaFraser$2.2M
- Thomas WubbenAnn Arbor$1.2M
- Manjool ShahAnn Arbor$745K
- Scott WesthouseGrand Rapids$525K
- Gregory KatzYpsilanti$495K
- Cagri BesirliAnn Arbor$441K
- David BrownSaint Joseph$432K
- Vinay AakaluAnn Arbor$429K
- David CookeSaint Joseph$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.